|Bid||55.51 x 500|
|Ask||55.52 x 1300|
|Day's Range||55.20 - 55.61|
|52 Week Range||46.01 - 76.80|
|PE Ratio (TTM)||19.29|
|Dividend & Yield||1.56 (2.85%)|
|1y Target Est||N/A|
Bristol-Meyers Squibb considers its people to be its competitive advantage, and it plans to build long-term, sustainable growth through innovation.
Celldex's clinical updates at ASCO failed to impress investors.
AstraZeneca stock rallied Friday on reports CEO Pascal Soriot will remain on board, defying rumors he would leave to take the top job at Teva Pharmaceutical.